Table 1 Demographic, clinical, cognitive, and site characteristics of participants in discovery and replication sets.

From: Neurobiology-based cognitive biotypes using multi-scale intrinsic connectivity networks in psychotic disorders

Characteristic

Replication

Discovery

Healthy Controls

N = 126

Relatives

N = 93

Patients

N = 256

Healthy Controls

N = 500

Relatives

N = 372

Patients

N = 923

BDPa

  

31

33%

60

23%

  

121

32%

250

27%

SADa

  

28

30%

96

38%

  

111

30%

299

32%

SZa

  

34

37%

100

39%

  

140

38%

374

41%

Demographic

 

Mean

SDb

Mean

SDb

Mean

SDb

Mean

SDb

Mean

SDb

Mean

SDb

Age (years)

35.55

12.94

41.66

15.88

37.69

11.79

35.92

12.20

41.12

15.59

36.74

12.20

Sex (Female)

74

60%

63

69%

137

54%

293

59%

237

64%

445

48%

SES

35.70

14.45

38.41

16.24

45.81

14.26

35.54

13.24

39.77

16.66

47.51

14.67

Ethnicity

 Hispanic

14

11%

6

6.5%

35

14%

65

13%

39

10%

111

12%

 Not Hispanic

112

89%

87

94%

219

86%

435

87%

333

90%

811

88%

 Not ascertainable

0

0%

0

0%

2

0.8%

0

0%

0

0%

1

0.1%

Race

 African American

33

26%

32

34%

98

38%

167

33%

100

27%

351

38%

 Caucasian

75

60%

61

66%

123

48%

264

53%

255

69%

469

51%

 Other

18

14%

0

0%

35

14%

69

14%

17

4.6%

103

11%

Clinical

 BSFS

154.87

15.43

149.20

23.98

122.25

22.76

154.21

17.40

146.51

21.25

124.79

24.61

 GAF

84.19

6.23

76.72

12.49

54.68

12.47

85.01

6.75

75.67

13.51

53.61

13.30

 MADRS

    

12.04

9.72

    

10.79

9.53

 PANSS

    

61.34

18.77

    

61.14

18.65

 SBS

    

5.11

2.62

    

5.22

2.85

 YMRS

    

8.31

6.67

    

8.04

7.45

Cognition

 BACS Composite Score

−0.17

1.18

−0.54

1.25

−1.48

1.39

−0.26

1.21

−0.48

1.32

−1.50

1.39

 BACS Verbal Memory

−0.11

1.13

−0.27

1.26

−1.01

1.33

−0.21

1.20

−0.36

1.22

−1.02

1.40

 BACS Digit Sequencing

−0.24

1.03

−0.31

1.18

−0.89

1.17

−0.22

1.06

−0.38

1.24

−0.96

1.24

 BACS Token Motor

−0.33

1.11

−0.69

0.99

−1.52

1.28

−0.49

1.22

−0.36

1.16

−1.44

1.16

 BACS Verbal Fluency

0.14

1.13

−0.11

1.29

−0.53

1.18

0.14

1.12

−0.11

1.12

−0.46

1.20

 BACS Symbol Coding

−0.08

1.00

−0.49

1.09

−1.08

1.20

−0.14

1.03

−0.46

1.08

−1.16

1.12

 BACS Tower of London

0.12

0.90

−0.14

0.96

−0.41

1.09

0.01

0.96

−0.11

1.00

−0.41

1.04

 WMS Spatial Span Forward

8.40

2.08

7.96

2.06

7.52

2.07

8.42

2.05

7.88

2.03

7.48

2.09

 WMS Spatial Span Backward

7.89

2.08

6.82

2.18

6.53

2.14

7.68

2.02

7.05

2.15

6.47

2.23

Medication

 ChlorEq

    

357.40

350.16

    

365.34

346.73

 Missing

    

0

    

540

Site

 Baltimore

9

7.1%

21

23%

18

7.0%

42

8.4%

87

23%

105

11%

 Boston

8

6.3%

2

2.2%

15

5.9%

26

5.2%

9

2.4%

68

7.4%

 Chicago

2

25%

12

13%

58

23%

113

23%

64

17%

229

25%

 Dallas

8

14%

13

14%

47

18%

96

19%

59

16%

145

16%

 Detroit

7

5.6%

7

7.5%

15

5.9%

15

3.0%

30

8.1%

36

3.9%

 Georgia

2

17%

0

0%

26

10%

81

16%

0

0%

89

9.6%

 Hartford

0

24%

38

41%

77

30%

127

25%

123

33%

251

27%

Dataset

 B-SNIP 1

7

37%

93

100%

95

37%

188

38%

372

100%

399

43%

 B-SNIP 2

79

63%

0

0%

151

63%

312

62%

0

0%

524

57%

  1. SES Socioeconomic Status, MADRS Montgomery-Asberg Depression Rating Scale, YMRS Young Mania Rating Scale, PANSS Positive and Negative Syndrome Scale for Schizophrenia, BSFS Birchwood Social Functioning Scale, GAF Global Assessment of Functioning Scale, SBS Schizo-bipolar Scale, BACS Brief Assessment of Cognition in Schizophrenia, WMS Weschler Memory Scale, ChlorEq average daily chlorpromazine dose.
  2. aFor relatives it is the diagnosis of their affected family member.
  3. bStandard Deviation.
Back to article page